Literature DB >> 6437674

Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations.

J K Willson, B H Long, M E Marks, D E Brattain, J E Wiley, M G Brattain.   

Abstract

A human colon carcinoma cell line resistant to mitomycin C (MMC) was obtained by repeated exposure of a previously described sensitive parental line, HCT 116, to MMC in vitro. Xenografts grown from the MMC-resistant phenotype were not inhibited in MMC-treated animals, while MMC treatment produced growth inhibition in parental cell xenografts. The MMC-resistant phenotype exhibited a greater amount of a Mr 148,000 cell surface protein than did the parental line. The increase in this Mr 148,000 cell surface protein correlated positively with the degree of MMC resistance. Alkaline elution of filter-bound DNA from resistant cells exposed to MMC in vitro showed a decrease in DNA cross-link formation such that a 10-fold higher MMC concentration was required to produce similar cross-link formation in the resistant cell as compared to the parental cell. The development of MMC resistance was not associated with in vitro cross-resistance to other natural product cytotoxic drugs. This model for resistance to MMC will be useful in future studies to define the mechanisms for MMC action and resistance in human colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Modulation of mitomycin C-induced multidrug resistance in vitro.

Authors:  R T Dorr; J D Liddil
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Immortalisation of a human diploid fibroblast cell strain: a DT-diaphorase paradox.

Authors:  B L Kuehl; C B Brezden; R D Traver; D Siegel; D Ross; J Renzing; A M Rauth
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Enhancement of the efficacy of mitomycin C-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiency.

Authors:  Preeyaporn Koedrith; Young Rok Seo
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

5.  Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.

Authors:  R R Perry; B R Greaves; Y Kang
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

Authors:  A Marinelli; D H Pons; J A Vreeken; S K Nagesser; P J Kuppen; U R Tjaden; C J van de Velde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.

Authors:  S S Pan; S A Akman; G L Forrest; C Hipsher; R Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.

Authors:  L J Wilkoff; E A Dulmadge; G Vasanthakumar; J P Donahue
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions.

Authors:  R S Marshall; M C Paterson; A M Rauth
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

10.  Further characterization of bleomycin-resistant HeLa cells and analysis of resistance mechanism.

Authors:  M Urade; M Sugi; T Matsuya
Journal:  Jpn J Cancer Res       Date:  1988-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.